<DOC>
	<DOCNO>NCT00322335</DOCNO>
	<brief_summary>This protocol post deal objective &amp; outcome measure extension phase Months 18 , 30 , 42 , 54 66 post booster . The objective &amp; outcome measure primary phase present separate protocol posting ( NCT number = NCT00352963 ) . The objective &amp; outcome measure Booster phase/study present separate protocol posting ( NCT number =NCT00323050 ) . The purpose study evaluate persistence meningococcal serogroup C Hib antibodies yearly basis period 5.5 year booster vaccination . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Long-term Persistence Study Assess Booster Dose GSK Biologicals ' Hib-MenC</brief_title>
	<detailed_description>This multicenter study open . No vaccine administer persistence phase study . The subject randomize primary vaccination study 217744/097 ( DTPa-HBV-IPV-097 ) randomize study . The study 3 group Meningitec™ prim group control . The protocol amend allow enrollment subject Meningitec™ prim control group boost Meningitec™ end booster study per new local reccommendation Spain .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol . A male female third year life time study initiation subject enter study Visit 1 . The subject enter study Visit 2 fourth year life time study initiation . Written inform consent obtain parent guardian subject . Healthy subject establish medical history clinical examination enter study . Having complete booster vaccination study HibMenCTT010 BST : DTPAHBVIPV097 ( NCT=00323050 ) . Subjects part Meningitec™ control group enrol Visit 1 enrol Visit 2 complete booster vaccination study HibMenCTT010 BST : DTPAHBVIPV097 ( NCT=00323050 ) receive fourth dose Meningitec™ second year life , booster study HibMenCTT010 BST : DTPAHBVIPV097 ( NCT=00323050 ) Previous administration booster dose Hib meningococcal serogroup C except booster study vaccine study HibMenCTT010 BST : DTPAHBVIPV097 . Subjects receive 4th dose Meningitec™ include study . History H. influenzae type b , meningococcal serogroup C diseases .</criteria>
	<gender>All</gender>
	<minimum_age>31 Months</minimum_age>
	<maximum_age>33 Months</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>H.influenzae type b Disease</keyword>
</DOC>